Free Trial
NASDAQ:ERAS

Erasca Q1 2023 Earnings Report

Erasca logo
$1.39 -0.01 (-0.71%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$1.39 0.00 (0.00%)
As of 04/25/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Erasca EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.30
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

Erasca Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Erasca Announcement Details

Quarter
Q1 2023
Time
N/A
Conference Call Date
Monday, May 15, 2023
Conference Call Time
11:00AM ET

Upcoming Earnings

Erasca's Q1 2025 earnings is scheduled for Wednesday, May 14, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Erasca Earnings Headlines

Erasca, Inc.: Carving A Different Niche In RAS Signaling
Erasca, Inc.: Carving A Different Niche In RAS Signaling
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Erasca (ERAS) Gets a Buy from J.P. Morgan
See More Erasca Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Erasca? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Erasca and other key companies, straight to your email.

About Erasca

Erasca (NASDAQ:ERAS), a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

View Erasca Profile

More Earnings Resources from MarketBeat